NCT03562949终止3 期
A Randomized, Multiple-Dose, Placebo-Controlled, Multi-Center Study Comparing Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg to QVAR® 40 mcg (Beclomethasone Dipropionate HFA), Inhalation Aerosol in Treatment of Subjects With Asthma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 761
- 试验地点
- 12
- 主要终点
- Baseline-adjusted, pre-dose FEV1 on the last day of the 4-week treatment period
研究概览
简要总结
To compare the efficacy and safety profiles of Beclomethasone dipropionate Inhalation Aerosol, 40 mcg (test product) and QVAR 40 mcg (beclomethasone dipropionate HFA), Inhalation Aerosol (reference product) and to demonstrate that the efficacy of the 2 active products is superior to that of placebo in the treatment of subjects with asthma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult male or female subjects of non-childbearing or of childbearing potential committing to consistent and correct use of an acceptable method of birth control.
- •Diagnosis of asthma as defined by the National Asthma Education and Prevention Program at least 12 months prior to screening.
- •Pre-bronchodilator FEV1 of >45% and <85% of predicted value during the screening visit and on the first day of treatment.
- •>15% and >0.20 L reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI).
- •Patients should be stable on their chronic asthma treatment regimen for at least four weeks prior to enrollment.
- •Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and having had <10 pack-years of historical use.
- •Ability to replace current short-acting β agonist (SABAs) with salbutamol/albuterol inhaler for use as needed for the duration of the study. Subjects should be able to withhold all inhaled SABAs for at least six hours prior to lung function assessments on study visits.
- •Ability to discontinue their asthma medications (inhaled corticosteroids and long-acting β agonists) during the run-in period and for remainder of the study.
- •Willingness to give their written informed consent to participate in the study.
排除标准
- •Life-threatening asthma, defined as a history of asthma episodes(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma related syncopal episode(s), or hospitalizations within the past year prior to the screening or during the run-in period.
- •Significant respiratory disease other than asthma (COPD, interstitial lung disease, etc.)
- •Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that, in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbates during the study.
- •Viral or bacterial, upper or lower respiratory tract infection, or sinus, or middle ear infection within four weeks prior to the screening, during the run-in period, or on the day of treatment.
- •Hypersensitivity to any sympathomimetic drug (e.g., albuterol) or any inhaled, intranasal, or systemic corticosteroid therapy.
- •Patients receiving β2-blockers, anti-arrhythmics, anti-depressants, and monoamine oxidase inhibitors within 4 weeks prior to the screening.
- •Patients who required systemic corticosteroids (for any reason) within the past 2 months.
研究组 & 干预措施
Test Product
Experimental
Test Product, 40 mcg, 2 x daily
干预措施: Test Product (Drug)
Reference Product
Active Comparator
Reference Product, 40 mcg, 2 x daily
干预措施: Reference Product (Drug)
Placebo
Placebo Comparator
Placebo Product 2 x daily
干预措施: Placebo (Drug)
结局指标
主要结局
Baseline-adjusted, pre-dose FEV1 on the last day of the 4-week treatment period
时间窗: 4 weeks
FEV1 measured in the morning prior dosing of inhaled medications on the last day of the 4-week treatment. The primary endpoint should be baseline adjusted (change from baseline).
次要结局
未报告次要终点
研究者
研究点 (12)
Loading locations...
相似试验
已完成
3 期
Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INHBronchial AsthmaNCT04051710Aurobindo Pharma Ltd1,550
已完成
3 期
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)Allergic RhinitisNCT01783548Teva Branded Pharmaceutical Products R&D, Inc.547
已完成
1 期
A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy AdultsPharmacokineticsNCT02030457Teva Branded Pharmaceutical Products R&D, Inc.72
已完成
4 期
Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent WheezingWheezingNCT02381158Istituto per la Ricerca e l'Innovazione Biomedica12
已完成
2 期
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent AsthmaAsthmaNCT02105012Pearl Therapeutics, Inc.147